Dr. Larry L. Kestin

  • MD, FACR
  • Radiation Oncologist
  • Spoken languages English


Career Positions

Current position(s)

  • GenesisCare - Medical Director, Michigan Region, Farmington Hills, MI

Past position(s)

  • GenesisCare - National Director of Thoracic and Lung Services, Farmington Hills, MI
  • Oakland University William Beaumont School of Medicine - Full Professor, Royal Oak, MI
  • Oakland Community College - Full Professor, Bloomfield Hills, MI



  • University of Missouri, BS, Computer Science, Columbia, MO
  • University of Kansas School of Medicine, Kansas City, KS


  • William Beaumont Hospital, Radiation Oncology, Chief Resident, Royal Oak, MI


  • William Beaumont Hospital, Rotating Program, Royal Oak, MI

Expertise And Interests


  • Lung / Thoracic, Lymphoma, Sarcoma, Prostate, GenitoUrinary Malignancies, Breast


Awards and honors

  • Best Doctors in America &


  • Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.
  • Cardiac Dose in Locally Advanced Lung Cancer: Results from a Statewide Consortium.
  • In Vivo Verification and Daily and Cumulative Dose Recalculation for Helical Tomotherapy: Multi Center Validation Based on Greater than 150,000 Daily Fractions Delivered
Expand Publications
View 1 more



E. Arrojo, E. Fernandez, L. Kestin, A. Martinez, 2016, ACRO

View Presentation


Martinez A, Olivera G, Ghilezan M, Forman J, Kestin L, Finkelstein S, Mo X, Key S, Mantz C, Fernandez E, Galmarini D, et al., 2015, ASTRO Annual Meeting

View Presentation


Kestin L, Fernandez E, Mantz C, Olivera G, Mo X, Key S, Finkelstein SE, Martinez A, Galmarini D., 2015, ASTRO Annual Meeting

View Presentation
Expand Presentations
View 1 more

Clinical studies

Primary Objective The primary goal of this study is to determine whether, in men with postprostatectomy PSA (prostate specific antigen) recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog, will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.

View Study

Larry Kestin's Reviews


based on 83 Ratings 19 Comments


everything fine


I was satified


Very positive experience in a difficult situation


Love this office....staff, nurses and doctors are friendly knowledgeable and caring!!

Read More

Ratings and Comments Powered by NRC Health